ACAD
NEUTRAL
$20.61
Live
ACADIA Pharmaceuticals Inc. · NASDAQ
Target $31.85
(+54.5%)
$13.4
52W Range
$28.35
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
78%
ACAD demonstrates strong financial health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and profitability. The company trades below its Graham Number ($19.31) and intrinsic value estimate ($67.85), suggesting potential undervaluation on a defensive basis. However, recent earnings growth has reversed sharply, with year-over-year EPS declining by 83.7% and Q/Q growth at -66.7%, raising concerns about sustainability. Insider selling activity over the past six months, totaling $1.17M, adds bearish sentiment despite the strong F-Score. Analysts remain optimistic with a buy recommendation and a target price of $31.85, but the current price is still significantly below intrinsic value.
Key Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
High gross margin (61.01%) and profit margin (36.49%) reflect strong pricing power and cost control
Extremely low debt/equity ratio (0.04) and high current/quick ratios (3.83/3.49) signal robust liquidity and minimal financial risk
Trading below Graham Number ($19.31) and intrinsic value ($67.85), suggesting potential undervaluation
Positive analyst consensus with 20 analysts recommending 'buy' and a target price of $31.85
Key Risks
Recent earnings growth has reversed sharply: YoY EPS down 83.7%, Q/Q EPS down 66.7%
Insider selling activity (4 transactions, $1.17M) over the last 6 months indicates potential lack of confidence
Forward P/E of 22.78 is high relative to current P/E of 8.96, suggesting market expects future growth that may not materialize
No Altman Z-Score available, but the absence of a score for a company with high growth and volatility raises caution
Revenue growth (9.40% YoY) is modest compared to sector peers averaging 137.58%, indicating slower top-line expansion
AI Fair Value Estimate
Based on comprehensive analysis
$67.85
+229.2% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ACAD against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ACAD from our newsroom.
Newest → oldest
No matching news yet.